BUB1B and cancer: In conclusion, our comprehensive pan-cancer analysis demonstrated that BUB1B is aberrantly expressed across various cancer types, with its expression levels significantly associated with clinicopathological characteristics and patient prognosis, particularly in lung adenocarcinoma.